Duco Twan Mülder

Duco Twan Mülder

Auto-generated profile, based on publicly available information

Duco Twan Mülder

Department of Public Health, Erasmus Medical Center, Rotterdam, The Netherlands

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 November 2025 in Gastroenterology
Verified
Journal Article
Open access
DMDuco T. Mülder
Duco T. Mülder
JOJames F. O’MAhony
James F. O’MAhony
NKNoa Kapteijn
Noa Kapteijn
TBTatjana Kofol Bric
Tatjana Kofol Bric
JHJudith Honing
Judith Honing
ILIris Lansdorp-Vogelaar
Iris Lansdorp-Vogelaar
Although Helicobacter pylori screen-and-treat has demonstrated effectiveness in preventing gastric cancer (GC), the impact on other diseases, such as peptic ulcer disease (PUD), dyspepsia, and gastric lymphomas, is often overlooked in guidelines and policy-analyses. This study quantifies the disease burden attributable to H pylori beyond GC. A systematic literature search identified studies reporting the relative risk of developing PUD, dyspepsia, or gastric lymphomas due to H pylori to calculate the population attributable fraction (PAF) for each condition. The PAF represents the proportion of disease burden caused by H pylori. Preventable case numbers were calculated based on the risk reduction from eradication, both globally and specific for countries with varying H pylori prevalence. The proportions of PUD, dyspepsia, and gastric lymphoma attributable to H pylori (95% confidence interval) were 57% (44%-68%), 7% (2%-13%), and 33% (12%-53%), respectively, corresponding to 3.5 (2.7-4.2) million, 30 (7.1-52.2) million, and 12,000 (4200-19,100) cases potentially preventable through eradication, globally. Country-specific estimates varied with lowest PAFs (PUD, dyspepsia, gastric lymphomas) observed in the United States (35% [24%-47%], 3% [2%-13%], and 17% [5%-31%]) and highest in South Korea (63% [50%-73%], 9% [2%-15%], and 39% [14%-58%]). However, even in the United States, preventable case numbers remained substantial for PUD (134,000 [93,000-177,000]) and dyspepsia (860,000 [196,000-1.5 million]). Omitting PUD and dyspepsia as outcomes in studies on H pylori screen-and-treat may substantially underestimate benefits. Incorporating these diseases alongside GC into cost-effectiveness and policy analyses, therefore, may improve the evaluation of H pylori screen-and-treat programs. The actual benefit depends on the extent to which H pylori triggers an irreversible pathway to disease early in life.

16 August 2023 in International Journal of Medical Informatics
Verified
Journal Article
Open access
DMDuco T. Mülder
Duco T. Mülder
RPRosita van Den Puttelaar
Rosita van Den Puttelaar
RMReinier G.S. Meester
Reinier G.S. Meester
JOJames F. O'MAhony
James F. O'MAhony
IVIris Lansdorp Vogelaar
Iris Lansdorp Vogelaar
Background: Identification of individuals at elevated risk can improve cancer screening programmes by permitting risk-adjusted screening intensities. Previous work introduced a prognostic model using sex, age and two preceding faecal haemoglobin concentrations to predict the risk of colorectal cancer (CRC) in the next screening round. Using data of 3 screening rounds, this model attained an area under the receiver-operating-characteristic curve (AUC) of 0.78 for predicting advanced neoplasia (AN). We validated this existing logistic regression (LR) model and attempted to improve it by applying a more flexible machine-learning approach. Methods: We trained an existing LR and a newly developed random forest (RF) model using updated data from 219,257 third-round participants of the Dutch CRC screening programme until 2018. For both models, we performed two separate out-of-sample validations using 1,137,599 third-round participants after 2018 and 192,793 fourth-round participants from 2020 onwards. We evaluated the AUC and relative risks of the predicted high-risk groups for the outcomes AN and CRC. Results: For third-round participants after 2018, the AUC for predicting AN was 0.77 (95% CI: 0.76–0.77) using LR and 0.77 (95% CI: 0.77–0.77) using RF. For fourth-round participants, the AUCs were 0.73 (95% CI: 0.72–0.74) and 0.73 (95% CI: 0.72–0.74) for the LR and RF models, respectively. For both models, the 5% with the highest predicted risk had a 7-fold risk of AN compared to average, whereas the lowest 80% had a risk below the population average for third-round participants. Conclusion: The LR is a valid risk prediction method in stool-based screening programmes. Although predictive performance declined marginally, the LR model still effectively predicted risk in subsequent screening rounds. An RF did not improve CRC risk prediction compared to an LR, probably due to the limited number of available explanatory variables. The LR remains the preferred prediction tool because of its interpretability.

1 September 2024 in Annals of Internal Medicine
Verified
Journal Article
Closed access
DMDuco T. Mülder
Duco T. Mülder
JOJames O'Mahony
James O'Mahony
CDChyke A. Doubeni
Chyke A. Doubeni
IVIris Lansdorp Vogelaar
Iris Lansdorp Vogelaar
MSMaartje H.N. Schermer
Maartje H.N. Schermer
Racial and ethnic disparities in incidence and mortality are well documented for many types of cancer. As a result, there is understandable policy and clinical interest in race- and ethnicity-based clinical screening guidelines to address cancer health disparities. Despite the theoretical benefits, such proposals do not typically address associated ethical considerations. Using the examples of gastric cancer and esophageal adenocarcinoma, which have demonstrated disparities according to race and ethnicity, this article examines relevant ethical arguments in considering screening based on race and ethnicity. Race- and ethnicity-based clinical preventive care services have the potential to improve the balance of harms and benefits of screening. As a result, programs focused on high-risk racial or ethnic groups could offer a practical alternative to screening the general population, in which the screening yield may be too low to demonstrate sufficient effectiveness. However, designing screening according to socially based categorizations such as race or ethnicity is controversial and has the potential for intersectional stigma related to social identity or other structurally mediated environmental factors. Other ethical considerations include miscategorization, unintended negative effects on health disparities, disregard for underlying risk factors, and the psychological costs of being assigned higher risk. Given the ethical considerations, the practical application of race and ethnicity in cancer screening is most relevant in multicultural countries if and only if alternative proxies are not available. Even in those instances, policymakers and clinicians should carefully address the ethical considerations within the historical and cultural context of the intended population. Further research on alternative proxies, such as social determinants of health and culturally based characteristics, could provide more adequate factors for risk stratification.

6 May 2025 in Helicobacter
Verified
Journal Article
Open access
DMDuco T. Mülder
Duco T. Mülder
JOJames F. O'MAhony
James F. O'MAhony
DSDianqin Sun
Dianqin Sun
LDLuuk A. van Duuren
Luuk A. van Duuren
RPRosita van Den Puttelaar
Rosita van Den Puttelaar
ILIris Lansdorp‐Vogelaar
Iris Lansdorp‐Vogelaar
Background: Recent American College of Gastroenterology (ACG) guidelines recommend screening and eradicating Helicobacter pylori (H. pylori) in high‐risk racial groups to prevent gastric cancer (GC), but do not provide guidance on the age to screen. We aimed to determine the optimal age for H. pylori screen‐and‐treat.Materials and Methods: We developed a new microsimulation model, MISCAN‐gastric, which was calibrated to SEER incidence and clinical studies on the natural history of GC. One‐time screen‐and‐treat at ages 20–65 was compared to a no‐screening scenario in terms of cumulative incidence reduction, number needed‐to‐screen (NNS) and number needed‐to‐treat (NNT) to prevent one GC case. The NNS represents the number of individuals that require testing to prevent one GC case, while the NNT reflects the number requiring treatment. The optimal age was investigated for a high‐risk population subgroup (non‐Hispanic [NH] Black males) and compared to other subgroups.Results: Without screening, 332 noncardia GC cases occurred in a population of 100,000 NH Black males. H. pylori screen‐and‐treat reduced cumulative incidence by 43% when performed at age 20, but only by 5% when performed at age 65. The NNS was lowest at age 30 and increased markedly at older ages. The estimated NNS for test‐ages 20, 30, 40, and 65 were 645, 563, 769, and 5487, respectively. The NNT was lowest at the youngest age (261) and increased with age to 448 at age 40 and 3681 at age 65. The NNT and NNS were substantially higher in groups with lower GC risk: the optimal NNT was four times higher in NH White females compared to non‐Hispanic Black males.Conclusion: H. pylori screen‐and‐treat maximized population benefits when performed before age 40, emphasizing the need for early interventions. When performed at the optimal age, the benefits of H. pylori screen‐and‐treat may outweigh the harms for high‐risk racial groups.

30 April 2025 in Gastroenterology
Verified
Journal Article
Open access
DMDuco T. Mülder
Duco T. Mülder
JOJames F. O’MAhony
James F. O’MAhony
MLMonika Laszkowska
Monika Laszkowska
JYJennifer Yeh
Jennifer Yeh
CHChin Hur
Chin Hur
ULUri Ladabaum
Uri Ladabaum
In the past year, two major American gastroenterology societies have introduced pivotal updates to their recommendations for gastric cancer (GC) prevention.1–3 The American College of Gastroenterology (ACG) released new guidelines on Helicobacter pylori management, recommending screen-and-treat to individuals at high-risk for GC,1 as well as guidelines on the management of gastric precursor lesions.2 Moreover, the American Gastroenterological Association (AGA) issued a clinical practice update (CPU) focusing on endoscopic screening and surveillance of high-risk groups for GC.3 These updates represent important advances in the rapidly evolving landscape of GC prevention. However, key differences in focus — between H pylori screen-and-treat vs endoscopic screening — may leave health care providers uncertain which to prioritize and which populations to consider for these interventions. In this commentary, we aim to provide a perspective on GC prevention integrating these recommendations, highlighting the unanswered questions they raise, and proposing new research avenues.

11 November 2024 in Cancer Epidemiology, Biomarkers & Prevention
Verified
Journal Article
Open access
DMDuco T. Mülder
Duco T. Mülder
HVHilliene J. van de Schootbrugge - Vandermeer
Hilliene J. van de Schootbrugge - Vandermeer
JOJames O'Mahony
James O'Mahony
DSDianqin Sun
Dianqin Sun
WHWeiran Han
Weiran Han
IVIris Lansdorp Vogelaar
Iris Lansdorp Vogelaar
Background: Identification of groups at a high risk of gastric cancer could facilitate targeted screening in countries with a low gastric cancer incidence. Our aim was to identify such high-risk groups based on individual-level population data on migration history and socioeconomic status (SES) in the Netherlands. Methods: In this retrospective cohort study, patient data from the Netherlands Cancer Registry were linked to demographic data of Statistics Netherlands in the period 2010 to 2022. Gastric cancer incidence rates in the 14 largest immigrant populations were compared with those born in the Netherlands. Odds ratios (OR) were computed per birthplace and controlled for age, sex, and SES. Additionally, we investigated gastric cancer risk among second-generation immigrants and by SES. Results: Immigrant populations at a significantly higher gastric cancer risk compared with the general population were identified. Specifically, foreign-born first-generation immigrants from Bosnia–Herzegovina (OR, 2.42), Turkey (OR, 2.22), and China (OR, 1.92) showed elevated risk. Whereas low SES increased the odds of developing gastric cancer, first-generation immigrants remained at higher risk even after controlling for SES. Second-generation immigrants did not have a significantly higher risk of developing gastric cancer. Conclusions: Certain first-generation immigrants remain at an elevated risk for gastric cancer despite migration to a low-risk region. Identification of these high-risk groups should be used to facilitate targeted gastric cancer prevention. Impact: Potential benefits of targeted Helicobacter pylori test-and-treat policy in immigrant populations should be explored in clinical and modeling studies. Primary care physicians should be cognizant of high-risk groups, facilitating the early detection of cancer within these populations.